Literature DB >> 10945022

[State of the treatment for gastrointestinal cancer].

H Baba1, S Kohnoe, K Endo, Y Ikeda, Y Toh, H Nakashima, T Okamura.   

Abstract

We reviewed the results of chemotherapy for gastrointestinal cancer. In Western countries, FAMTX or ECF is recognized as the standard therapy for gastric cancer. In Japan, no standard chemotherapeutic regimen has been established yet, but FP or MTX/5-FU are often used as a first line chemotherapy. There have been only a few clinical trials of adjuvant chemotherapy for gastric cancer in which this regimen was identified as having a statistically significant effect. For colon cancer, 5-FU plus LV are now used as the standard therapy. Recently, however, it has been shown that 5-FU + LV combined with CPT-11 is more active than 5-FU + LV alone. The efficacy of oral anticancer agents such as UFT + LV, S-1, and capecitabin have also been shown to be equally or more active than i.v. administration of 5-FU and LV, so that the standard therapy for colon cancer will be changed in near future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945022

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.

Authors:  Go Nakajima; Kazuhiko Hayashi; Yaguang Xi; Kenji Kudo; Kazumi Uchida; Ken Takasaki; Masakazu Yamamoto; Jingfang Ju
Journal:  Cancer Genomics Proteomics       Date:  2006-10       Impact factor: 4.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.